Abstract:BACKGROUND: Semaphorin 4D (Sema4D) belongs to the class IV semaphorins, and accumulating evidence has indicated that its elevated level may be one strategy by which tumors evade current anti-angiogenic therapies. The biological roles of Sema4D in colorectal cancer (CRC), however, remain largely undefined. This study was designed to investigate the effects of Sema4D on tumor angiogenesis and growth in CRC, especially in different vascular endothelial growth factor (VEGF) backgrounds.METHODS: The expression of Sema4D in human CRC was evaluated by immunohistochemical analysis of tumors and their matching normal control tissues. The expression level of Sema4D and VEGF was investigated in different CRC cell lines. To evaluate the contributions of Sema4D to tumor-induced angiogenesis, two CRC cell lines with opposite VEGF backgrounds were infected with lentiviruses expressing Sema4D or Sema4D short hairpin RNA, followed by in vitro migration and in vivo tumor angiogenic assays.RESULTS: Immunohistochemical analysis of human CRC revealed high levels of Sema4D in a cell surface pattern. In all, 84.85% of CRC samples analyzed exhibited moderate to strong Sema4D expression. The positive ratios of Sema4D staining for well, moderately, and poorly differentiated cancers were 71.43%, 96.67%, and 77.27%, respectively. Sema4D is highly expressed in five different CRC cell lines, while VEGF expression level varies among these cell lines. HCT-116 showed the lowest VEGF level, while Caco-2 showed the maximum VEGF level. In vitro migration results show that regardless of cell type and VEGF background, Sema4D showed an enhanced in vitro proangiogenic effect to induce the migration of human umbilical vein endothelial cells. Finally, in vivo tumor angiogenic assays demonstrated that Sema4D alone can elicit a significant angiogenic response to promote tumor growth independently of VEGF.CONCLUSION: Targeting Sema4D might serve as a parallel option for antiangiogenic therapy for CRC, particularly when traditional anti-VEGF therapies fail or tumors develop resistance to strategies targeting a single angiogenic signaling pathway.

Semaphorins as Potential Immune Therapeutic Targets for Cancer

Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis.

Semaphorins in tumor microenvironment: Biological mechanisms and therapeutic progress

Targeting the CD47-SIRPα Signaling Axis: Current Studies on B-cell Lymphoma Immunotherapy

Dongjun Jiang, Xiaoli Chen, Xiuting Li, Jian Qiu, Peng Xu, Xuezhi Li

Tumor Immune Checkpoints and Their Associated Inhibitors

Myeloid-derived Suppressor Cells: Connection Between Inflammation and Cancer

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Semaphorin 4B promotes tumor progression and associates with immune infiltrates in lung adenocarcinoma

The role of semaphorin 4D as a potential biomarker for antiangiogenic therapy in colorectal cancer

Integrins in cancer: Emerging mechanisms and therapeutic opportunities

Targeting Innate Sensing in the Tumor Microenvironment to Improve Immunotherapy

The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy

Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy

RFC: Range feature code for TCAM-based packet classification

The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy

Semaphorins in immune cell function, inflammatory and infectious diseases

Sialic acid and Siglec receptors in tumor immunity and immunotherapy

Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy

Innate Immunity in Cancer Biology and Therapy